For the first time, the American Heart Association, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists, and the Society for Maternal-Fetal Medicine have joined forces to release shared guidance aimed at helping clinicians identify cardiovascular risk early and take action. The landmark three-part publication, published in the American Heart Association's flagship journal Circulation, highlights how female-specific biology affects girls' and women's hearts and creates a "Female Life Stage" framework to help protect heart health from puberty through menopause and beyond. The societies also call for a national network of Comprehensive Centers of Excellence for Women's Cardiovascular Care, built on four pillars: interdisciplinary clinical care, professional education and training, research, and community engagement.
The importance of this coordinated effort is underscored by stark statistics. According to the American Heart Association, cardiovascular disease, which includes heart disease and stroke, is the leading cause of death in women, claiming more than 400,000 lives in the U.S. each year—more than breast cancer, lung cancer, and chronic lung disease combined. Yet only about 4 in 10 women recognize it as their greatest health threat. A 2026 American Heart Association scientific statement projected that if trends continue through 2050, the proportion of U.S. women ages 20 and older living with high blood pressure will increase from approximately 49% in 2020 to 59% in 2050. At the same time, maternal mortality has increased, and cardiovascular disease is now the leading cause of medical-related deaths during pregnancy, accounting for more than one-third of maternal mortality in the U.S.
The new Female Life Stage framework is based on female biology and offers windows of opportunity to prevent heart disease and stroke. It defines four stages: perimenarche (ages 8-15), ovarian cycling (ages 15-44), perimenopause (ages 45-51), and postmenopause (51 and older), with pregnancy recognized as a biological "stress test" that can occur at any stage. "For clinicians, this approach underscores that heart health cannot be understood by looking at the heart alone," said Sadiya S. Khan, M.D., M.Sc., FAHA, chair of the collaborative writing group. "We need to recognize that women's heart health is deeply interconnected with hormonal and emotional health." The framework also emphasizes that Perimenopause is a cardiovascular inflection point, and that menstrual cycle patterns can serve as a female-specific vital sign.
The publications address critical gaps in care, including the fact that only about 60% of U.S. women with high blood pressure-related complications during pregnancy receive follow-up care within six months of delivery. The 2026 American Heart Association/American College of Cardiology cholesterol guideline now includes pregnancy-related factors in cardiovascular risk assessment for women. The societies also point to the American Heart Association's PREVENT equations, which allow for 10- and 30-year sex-specific risk estimation. The three papers—a A Female-Specific Life Course Approach to the Prevention and Management of Cardiovascular Disease, a Consensus Guidance for the Female-Specific Prevention and Management of Cardiovascular Disease, and a Comprehensive Centers of Excellence for Women's Cardiovascular Care—provide a shared foundation for clinicians across specialties. "All girls and women deserve more healthy years to live their fullest lives," Khan said. "Advancing women's health is a responsibility we all share."
